Back to the list
Congress: ECR25
Poster Number: C-27305
Type: Poster: EPOS Radiologist (educational)
DOI: 10.26044/ecr2025/C-27305
Authorblock: R. Rocha De Almeida; Boston, MA/US
Disclosures:
Renata Rocha De Almeida: Nothing to disclose
Keywords: Abdomen, Nuclear medicine, Oncology, MR, PET-CT, PET-MR, Ablation procedures, Biopsy, Metastases, Molecular, genomics and proteomics, Neoplasia
References

[1] Houghton, R. M., et al. "Prostate-specific membrane antigen PET imaging in prostate cancer." The Journal of Nuclear Medicine, 2021.

[2] Fendler, W. P., et al. "PSMA PET imaging and its role in the diagnosis and treatment of prostate cancer." European Urology, 2017.

[3] Silver, D. A., et al. "Prostate-specific membrane antigen expression in normal and malignant human tissues." The Journal of Urology, 1997.

[4] Giesel, F. L., et al. "PET/CT with [68Ga]PSMA-11 in prostate cancer." The Journal of Nuclear Medicine, 2017.

[5] Rahbar, K., et al. "PSMA-targeted radioligand therapy in prostate cancer." European Journal of Nuclear Medicine and Molecular Imaging, 2020.

[6] von Eyben, F. E., et al. "PET/CT imaging for detection of prostate cancer recurrence." The Prostate, 2020.

[7] Eiber, M., et al. "Prostate cancer: PSMA PET/CT imaging and its potential role in clinical practice." Radiology, 2016.

[8] Kranzbühler, B., et al. "Lutetium-177 PSMA-617 therapy in metastatic castration-resistant prostate cancer: a systematic review." European Journal of Nuclear Medicine and Molecular Imaging, 2021.

[9] Cooney, M. M., et al. "Dedifferentiated prostate cancer and loss of PSMA expression." European Urology Oncology, 2020.

[10] Uprimny, C., et al. "Post-therapy PET imaging with [68Ga]PSMA-11 in prostate cancer: implications for treatment monitoring." European Journal of Nuclear Medicine and Molecular Imaging, 2020.

 
GALLERY